Plymouth, MN, USA and Ecouen, France, October 8, 2018 – Interrad Medical, a privately held medical device company, announces an agreement with Vygon to distribute the SecurAcath Subcutaneous Catheter Securement Device in France. “As we continue to expand global distribution, we are very excited to be able to enter the French market with Vygon as a partner,” commented Joe Goldberger, President and CEO of Interrad Medical. Thomas Walter, Vice President Vygon Intravascular Therapies Business Unit stated, “We are pleased to be able to commercialize the SecurAcath in France. The SecurAcath is a perfect fit with the Vygon portfolio of products and we anticipate it will become the market leading catheter securement device.” The SecurAcath is the only subcutaneous catheter securement device that lasts the life of the line and can dramatically decrease catheter dislodgement and migration, decrease catheter replacement costs, prevent therapy interruption, reduce catheter-related infections and other complications, and lower total cost of patient care.
About Interrad Medical, Inc.
Plymouth, Minnesota-based Interrad Medical, Inc. is a developer, manufacturer and marketer of medical devices designed for minimally-invasive interventional and surgical procedures. Learn more at www.securacath.com.
About Vygon Group
Vygon designs, manufactures and markets high-tech single-use medical devices for healthcare professionals in hospital and for private and independent practitioners. Vygon is a world leader within this industry, offering a wide range of products in a number of clinical specialties. Organized in five business units (Intensive Care – Neonatology, Enteral & Obstetrics – Intravascular Therapies – Cardiovascular & Surgery – Anesthesia & Emergency), Vygon combines local and international in-depth expertise and know-how in each individual field.
With expertise right along the value chain, from product design to the delivery of training for medical personnel, Vygon provides health care professionals with effective and innovative products tailored to their needs and those of their patients, for optimum use and safety. The company distributes over 205 million products a year in more than 120 countries through its network of 27 subsidiaries and 331 distributors. Vygon products display the CE and/or FDA mark and are manufactured in the group’s eight factories in Europe, the USA and Colombia. A family company founded in 1962, Vygon is based in Ecouen, in France’s Greater Paris region. It is a mid-sized business employing 2,350 staff worldwide. The turnover in 2017 was €310 million ($362M), with 81% of this derived from
Vygon’s international business. www.vygon.com.
This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with litigation, clinical trials, the regulatory approval process, reimbursement policies and commercialization of new technologies.